The strongest evidence for an action of lubiprostone through CFTR rather than ClC-2 activation comes from a study using mice that were genetically deficient in CFTR and biopsy intestinal tissue from CF patients [19]. The gene discussed is CFTR; the disease is cystic fibrosis.